Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Next Previous
Trial Profile

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonapegsomatropin (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms foresiGHt
  • Sponsors Ascendis Pharma

Most Recent Events

  • 12 Feb 2026 According to an Teijin Pharma media release, based on results from this study company has applied for manufacturing and marketing approval in Japan for lonapegsomatropin. The application has been submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026.
  • 28 Jul 2025 According to an Ascendis Pharma media release,based on results from this trial , the U.S. Food & Drug Administration (FDA) has approved SKYTROFA for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
  • 05 May 2025 According to an Ascendis Pharma media release, data from this study will be presented at the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top